Close

Refine your search

Elena Puris

Elena Puris

Academy Research Fellow

PhD

elena.puris@uef.fi

Information Publications

My research interests include investigating the roles of membrane transporters (SLCs and ABCs) and receptors expressed at barrier sites in pathogenesis of CNS diseases, in particular in Alzheimer’s disease, as well as in drug delivery and pharmacokinetics.  In addition, my research focuses on identifying novel drug targets for the treatment of Alzheimer’s disease. Another goal of my research is to facilitate CNS drug development by characterizing different in vitro and in vivo models for studying the blood-brain barrier and membrane transporters/receptors.

Research groups

Publications

  1. Petralla, S., Panayotova, M., Franchina, E., Fricker, G., Puris, E. (2024). Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer’s Disease. Pharmaceutics, 16(7), 948.
  2. Puris, E., Saveleva, L., Auriola, S., Gynther, M., Kanninen, K. M., Fricker, G. (2024). Sex-specific changes in protein expression of membrane transporters in the brain cortex of 5xFAD mouse model of Alzheimer’s disease. Frontiers in Pharmacology. 15:1365051
  3. Petralla, S., Saveleva, L., Kanninen, K.M., Oster, J.S., Panayotova, M., Fricker, G., Puris, E. (2024). Increased expression of transferrin receptor 1 in the brain cortex of 5xFAD mouse model of Alzheimer’s disease is associated with activation of HIF-1 signalling pathway. Molecular neurobiology. 1007/s12035-024-03990-3. Advance online publication.
  4. Puris, E., Saveleva, L., de Sousa, Maciel I., Kanninen, K. M., Auriola, S., Fricker, G. (2023) Protein expression of amino acid transporters is altered in isolated cerebral microvessels of 5xFAD mouse model of Alzheimer’s disease. Molecular neurobiology. 60(2): 732–748.
  5. Puris, E., Petralla, S., Auriola, S., Kidron, H., Fricker, G., Gynther, M. (2023). Monoacylglycerol lipase inhibitor JJKK048 ameliorates ABCG2 transporter-mediated regorafenib resistance induced by hypoxia in Triple Negative Breast Cancer cells. Journal of pharmaceutical sciences. 112(9), 2581–2590.
  6. Puris, E., Fricker, G., Gynther, M. (2023). The role of Solute carrier transporters in efficient anticancer drug delivery and therapy. Pharmaceutics, 15(2), 364.
  7. Eteläinen, T. S., Silva, M. C., Uhari-Väänänen, J. K., De Lorenzo, F., Jäntti, M. H., Cui, H., Chavero-Pieres, M., Kilpeläinen, T., Mechtler, C., Svarcbahs, R., Seppälä, E., Savinainen, J. R., Puris, E., Fricker, G., Gynther, M., Julku, U. H., Huttunen, H. J., Haggarty, S. J., & Myöhänen, T. T. (2023). A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. Science translational medicine. 15(691).
  8. Ozgür, B., Puris, E., Brachner, A., Appelt-Menzel, A., Oerter, S., Balzer, V., Holst, M. R., Christiansen, R. F., Hyldig, K., Buckley, S. T., Kristensen, M., Auriola, S., Jensen, A., Fricker, G., Nielsen, M. S., Neuhaus, W., Brodin, B. (2023). Characterization of an iPSC-based barrier model for blood-brain barrier investigations using the SBAD0201 stem cell line. Fluids and barriers of the CNS. 20(1), 96.
  9. Puris, E., Auriola, S., Hartman, R., Gynther, M., de Lange, E.C.M., Fricker, G. (2022) Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer’s disease model. Neurobiology of Disease. 169: 105741.
  10. Puris, E., Saveleva, L., Górová, V., Vartiainen, P., Kortelainen, M., Lamberg, H., Sippula, O., Malm, T., Jalava, P. I., Auriola, S., Fricker, G., & Kanninen, K. M. (2022). Air pollution exposure increases ABCB1 and ASCT1 transporter levels in mouse cortex. Environmental toxicology and pharmacology. 96, 104003.
  11. Puris, E., Fricker, G., Gynther, M. (2022) Targeted brain drug delivery via transporters: can we do better? Pharmaceutical Research. 39(7): 1415-1455.
  12. Balzer, V., Poc, P., Puris, E., Martin, S., Aliasgari, M., Auriola, S., Fricker, G. (2022) Evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies. European Journal of Pharmaceutics and Biopharmaceutics, 173: 12-21.
  13. Gynther, M., Estrada, M. L., Loppi, S., Korhonen, P., Kanninen, K. M., Malm, T., Koistinaho, J., Auriola, S., Fricker, G., Puris, E. (2022). Increased Expression and Activity of Brain Cortical cPLA2 Due to Chronic Lipopolysaccharide Administration in Mouse Model of Familial Alzheimer’s Disease. Pharmaceutics. 14(11), 2438.
  14. Puris, E., Kouřil, Š., Najdekr, L., Auriola, S., Korhonen, P., Loppi, S., Gómez-Budia, M., Fricker G., Kanninen, K. M., Malm, T., Friedecký, D., Gynther, M. (2022): Metabolomic, lipidomic and proteomic characterisation of lipopolysaccharide-induced inflammation mouse model. Neuroscience. 496: 165-178.
  15. Puris, E., Jalkanen, A., Auriola, S., Korhonen, P., Loppi, S., Kanninen, K. M., Malm, T., Koistinaho, J., Gynther, M. (2022) Systemic inflammation elevates cytosolic prolyl oligopeptidase protein expression but not peptidase activity in the cerebral cortices of familial Alzheimer`s disease modeling mice. Brain Disorders. 6: 100035.
  16. Puris, E., Kouřil, Š., Najdekr, L., Loppi, S., Korhonen, P., Kanninen, K. M., Malm, T., Koistinaho, J., Friedecký, D., Gynther, M. (2021) Metabolomic and lipidomic changes triggered by lipopolysaccharide-induced systemic inflammation in transgenic APdE9 mice. Scientific Reports. 11(1): 13076.
  17. Puris, E., Auriola, S., Korhonen, P., Loppi, S., Kanninen, K. M., Malm, T., Koistinaho, J., Gynther, M. (2021) Systemic inflammation induced changes in protein expression of ABC transporters and ionotropic glutamate receptor subunit 1 in the cerebral cortex of familial Alzheimer`s disease mouse model. Journal of Pharmaceutical Sciences. 110(12): 3953-3962.
  18. Mahringer, A., Puris, E., & Fricker, G. (2021): Crossing the blood-brain barrier: A review on drug delivery strategies using colloidal carrier systems. Neurochemistry international. 147: 105017.
  19. Puris, E., Gynther, M., Auriola, S., Huttunen, K.M. (2020) L-Type amino acid transporter 1 as a target for drug delivery. Pharmaceutical Research. 37(5): 88.
  20. Puris, E., Pasanen, M., Ranta, V-P., Gynther, M., Petsalo, A., Käkelä, P., Männisto, V., Pihlajamäki, J. (2019) Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 125: 123-132.
  21. Puris, E., Gynther, M., de Lange, E.C.M., Auriola, S., Hammarlund-Udenaes, M., Huttunen, K.M., Loryan, I. (2019) Mechanistic study on the use of the L-type amino acid transporter 1 for brain intracellular delivery of ketoprofen via prodrug: a novel approach supporting the development of prodrugs for intracellular targets. Molecular Pharmaceutics. 16(7): 3261-3274.
  22. Puris, E., Gynther, M., Huttunen, J., Auriola, S., Huttunen, K.M. (2019) L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery. Eur J Pharm Sci. 129: 99-109.
  23. Gynther, M., Puris, E., Peltokangas, S., Auriola, S., Kanninen, K.M., Koistinaho, J., Huttunen, K.M., Ruponen, M., Vellonen, K.S. (2018) Alzheimer’s disease phenotype or inflammatory insult does not alter function of L-type amino acid transporter 1 in mouse blood-brain barrier and primary astrocytes. Pharmaceutical Research. 36(1): 17.
  24. Puris, E., Gynther, M., Huttunen, J., Petsalo, A., Huttunen, K.M. (2017) L-type amino acid transporter 1 utilizing prodrugs: how to achieve effective brain delivery and low systemic exposure of drugs. J Control Release. 261: 93-104.
  25. Puris, E., Pasanen, M., Gynther, M., Häkkinen, M.R., Pihlajamäki, J., Keränen, T., Honkakoski, P., Raunio, H., Petsalo, A. (2017) A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine. Anal Bioanal Chem. 409(1): 251-268.
  26. Huttunen, K.M., Gynther, M., Huttunen, J., Puris, E., Spicer, J.A., Denny, W.A. (2016) A selective and slowly reversible inhibitor of l-type amino acid transporter 1 (LAT1) potentiates antiproliferative drug efficacy in cancer cells. J Med Chem. 59(12): 5740-51.1.

Keywords

Alzheimer's disease blood-brain barrier drug delivery pharmacokinetics transporters

Publications

11/11 items